A Phase 3 trial for Northwest Biotherapeutics’s DCVax-L vaccine extended survival in patients with gliobastoma for many months, or in some cases, years: according to new data.

Cybin Inc. today announced that it will discuss its topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive...

/PRNewswire/ -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced it is teaming up with football icon, Emmitt Smith, to break down the stigma around...

Cassava Sciences has finished enrolling participants in a Phase III trial of an oral drug candidate, simufilam, to treat Alzheimer's disease.

Biora Therapeutics has

MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering,...

Cassava Sciences has reported that drug effects of simufilam in the Phase II trial favoured patients with mild Alzheimer’s disease.

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering,...

Safety Finding Based on Blinded MRI Brain Data at Week 40ARIA is a Known Risk Factor for Anti-Amyloid Antibody DrugsMRI Data Presented at the 16th CTAD...

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled

We respond to preliminary overall survival data from phase III clinical trial that suggests DCVax-L may help extend survival for patients with newly-diagnosed or recurrent glioblastomas.

Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.

Ocugen Inc said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States.

Immunogen CEO Mark Enyedy describes Elahere’s MIRASOL trial result and what it means for ovarian cancer and ADCs.

H.C. Wainwright Stick to Their Buy Rating for Humanigen

Ocugen, Inc. announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medici...

MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering,...

MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering,...

Takeda bet $300 million upfront and promised more than twice that in milestones to work on Arrowhead Pharmaceuticals’ RNA-silencing treatment. | Takeda bet $300 million upfront and promised more than...

Stargardt disease is an orphan blindness disease that affects approximately 35,000 people in the United States.

Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa.,...

In a boost to accelerate clinical enrollments, Revive Therapeutics has followed Big Pharma's footsteps and gone international.

/PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today development of a novel immunotherapy for treatment of solid tumors....

Revive Therapeutics is on track to seek approval from the FDA to amend the third phase endpoints of its Bucillamine trial.

Ocugen, Inc. announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa, OCU410 for the treatment of geogra...

The FDA's Vaccines and Related Biological Products Advisory Committee is set to review clinical data on June 7 and potentially suggest approval of NVX-CoV2373.

Autonomix Medical, Inc. announced its common stock will begin trading on the NASDAQ today Monday, January 29, 2024 at approximately 10:30 am EST under the ticker symbol “AMIX.”

MALVERN, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering,...

Novavax Inc said on Monday it would pursue full approval of its COVID-19 vaccine in the second half of this year and forecast total revenue of between $4 billion and $5 billion for 2022.

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, and Catalent (NYSE:...

Novavax CEO Stanley Erck joins Yahoo Finance Live to discuss expectations for the upcoming FDA advisory meeting vote regarding the Novavax COVID-19 vaccine, stock data, and the outlook for the future...

With megablockbuster Keytruda’s patent cliff looming in 2028, Merck has made some bold M&A moves in an attempt to find its next big moneymaker, including last year’s $11.5 billion acquisition of...

Unfortunately, the battle against Covid-19 is an ongoing concern, and companies are still lining up to find solutions to fend off the virus. One such name with a potential treatment is small cap...

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it has completed enrollment of the...

TORONTO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

UK’s MHRA accepts Humanigen’s submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review

Trial results suggest people with newly diagnosed glioblastoma could potentially be given extra years of life

TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use AuthorizationTORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revi...

The trial will evaluate, BNT111, a therapeutic mRNA-based cancer vaccine in combination with Libtayo® for the treatment of melanoma.

DSMB support in continuing the Phase 3 clinical trial; No serious adverse events and safety concerns reported to date.Phase 3 clinical trial to incorporate viral load testing for a minimum of 300...

/PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering,...

Combination treatment with etigilimab and nivolumab was well tolerated in patients with recurrent or advanced solid tumors and promising efficacy was seen for patients with PD-L1 low disease

Ocugen, Inc. today announced that it will host an in-person Clinical Showcase on Wednesday, February 21, 2024.

Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals.

The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26,...

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development...

MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering,...

Inovio Pharmaceuticals hopes to begin trials on humans this summer

Revive Therapeutics submitted their Data Access Plan to the FDA—a key step required, pending FDA approval, to view unblinded Ph3 patient data

/PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023, October...

TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

Novel iNKT agonist leads to a broad reprogramming of the innate and adaptive immune system to target cancerPORT-2 has the potential to re-sensitize checkpoint-resistant tumors to treatment with PD-1...

Ocugen, Inc. today announced that dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV- hRORA ).

TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) announces that it is expanding its previously announced private placement (see...

Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment in Turkey by mid-FebruaryExpected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 (GLOBE...

Revive Therapeutics Ltd. is pleased to announce it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. to evaluate the delivery of 3,4-Methylenedioxy​methamphetamine...

Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical TrialDSMB Determination to Proceed with Medium Dose Cohort Dosing ...

BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract development...

Lucid Diagnostics to hold a Business Update Conference Call on May 11, 2022.

Incannex Healthcare, an Australian developer of synthetic cannabidiol and psychedelic medicine therapies, announced terms for its IPO on Tuesday.

MONTREAL, July 20, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...